Trinity Biotech plc
TRIB
$0.6792
$0.000.00%
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 13.99% | -14.61% | -6.54% | -24.73% | -28.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.99% | -14.61% | -6.54% | -24.73% | -28.63% |
| Cost of Revenue | 13.99% | -14.39% | -32.38% | -25.71% | 17.33% |
| Gross Profit | 14.00% | -15.03% | 1,200.91% | -22.94% | -96.30% |
| SG&A Expenses | -18.75% | -28.26% | 49.15% | 22.39% | -15.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 81.69% | -- | -6,900.00% | -7,000.00% | 97.67% |
| Total Operating Expenses | -2.37% | -18.86% | -11.00% | -7.45% | 6.48% |
| Operating Income | 58.71% | 31.88% | 22.98% | -341.20% | -430.49% |
| Income Before Tax | 62.99% | 47.19% | 34.93% | -91.22% | -723.74% |
| Income Tax Expenses | 50.94% | 76.92% | 11,000.00% | -820.69% | -99.20% |
| Earnings from Continuing Operations | 63.17% | 47.16% | 32.72% | -89.04% | -839.85% |
| Earnings from Discontinued Operations | -- | -- | -100.10% | 1,235,900.00% | 3,696.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.84% | 45.41% | 24.86% | 38.31% | -777.14% |
| EBIT | 58.71% | 31.88% | 22.98% | -341.20% | -430.49% |
| EBITDA | 57.39% | 32.63% | 16.24% | -443.27% | -300.43% |
| EPS Basic | 8.72% | 44.11% | 25.30% | 45.28% | -471.36% |
| Normalized Basic EPS | 47.17% | -- | -- | -6.98% | -- |
| EPS Diluted | 8.72% | 43.67% | 25.69% | 45.31% | -493.33% |
| Normalized Diluted EPS | 47.17% | -- | -- | -6.98% | -- |
| Average Basic Shares Outstanding | 23.62% | 13.61% | 0.58% | 12.76% | 82.32% |
| Average Diluted Shares Outstanding | 23.62% | 13.61% | 0.58% | 12.75% | 74.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
